260 related articles for article (PubMed ID: 33948712)
21. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.
Hua X; Yin Z; Liang J; Chen W; Gong H
Eur J Gastroenterol Hepatol; 2024 Jan; 36(1):120-128. PubMed ID: 37942731
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan.
Yamashita T; Suzuki N; Motoyoshi K; Zhu W; Furuse J
PLoS One; 2024; 19(3):e0298420. PubMed ID: 38457389
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer.
Yamazaki H; Iwasaki H; Takasaki H; Suganuma N; Sakai R; Masudo K; Nakayama H; Rino Y; Masuda M
Medicine (Baltimore); 2019 Mar; 98(10):e14774. PubMed ID: 30855484
[TBL] [Abstract][Full Text] [Related]
24. Sustained antitumor response to lenvatinib with weekend-off and alternate-day administration in chemotherapy-refractory thymic carcinoma: a case report.
Sunaga N; Miura Y; Sakurai R; Ohshima S; Uno S; Muto S; Sato M; Tsurumaki H; Yatomi M; Koga Y; Ohtaki Y; Nagashima T; Okano N; Kubo N; Maeno T; Hisada T
Anticancer Drugs; 2023 Apr; 34(4):605-608. PubMed ID: 36729850
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
Chen K; Wei W; Liu L; Deng ZJ; Li L; Liang XM; Guo PP; Qi LN; Zhang ZM; Gong WF; Huang S; Yuan WP; Ma L; Xiang BD; Li LQ; Zhong JH
Cancer Immunol Immunother; 2022 May; 71(5):1063-1074. PubMed ID: 34559308
[TBL] [Abstract][Full Text] [Related]
26. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.
Une N; Takano-Kasuya M; Kitamura N; Ohta M; Inose T; Kato C; Nishimura R; Tada H; Miyagi S; Ishida T; Unno M; Kamei T; Gonda K
Med Oncol; 2021 Apr; 38(6):60. PubMed ID: 33881631
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.
Wang XH; Liu CJ; Wen HQ; Duan XH; Jiao YQ; Liu YJ; Chen MS; Zhu KS; Mao XH; Zhou QF
Clin Transl Med; 2023 Mar; 13(3):e1214. PubMed ID: 36855781
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ; Taylor MH; Evans TRJ; Okusaka T; Glen H; Lubiniecki GM; Dutcus C; Smith AD; Okpara CE; Hussein Z; Hayato S; Tamai T; Makker V
Expert Rev Anticancer Ther; 2022 Apr; 22(4):383-400. PubMed ID: 35260027
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors.
Yuan F; Lenneman C; Krone R; Williams GR; Outlaw D; Katsnelson M; Lirette S
Pharmacotherapy; 2024 Mar; 44(3):214-223. PubMed ID: 38009283
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
Wang Q; Ji X; Sun J; Zhang A; Jia J; Zhang T; Li W; Duan X
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38583495
[TBL] [Abstract][Full Text] [Related]
33. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review.
Crotty P; Kari K; Hughes GK; Ladd C; McIntire R; Gardner B; Peña AM; Ferrell S; Tuia J; Cohn J; Haslam A; Prasad V; Vassar M
Target Oncol; 2024 Mar; 19(2):161-173. PubMed ID: 38466535
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma.
Tateai Y; Kawakami K; Teramae M; Fukuda N; Yokokawa T; Kobayashi K; Shibata N; Suzuki W; Shimizu H; Takahashi S; Ozaka M; Sasahira N; Hori S; Yamaguchi M
PLoS One; 2023; 18(11):e0294320. PubMed ID: 37972015
[TBL] [Abstract][Full Text] [Related]
35. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
Fujiwara K; Kondo T; Fujimoto K; Yumita S; Ogawa K; Ishino T; Nakagawa M; Iwanaga T; Tsuchiya S; Koroki K; Kanzaki H; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Ogasawara S; Nakamoto S; Chiba T; Koizumi J; Kato J; Kato N
J Gastroenterol; 2024 Jun; 59(6):515-525. PubMed ID: 38583112
[TBL] [Abstract][Full Text] [Related]
36. Systematic review of the efficacy and safety of lenvatinib in various solid tumors.
Geng S; Liu T; Wang N; Gao X; Luo X; Shi N; Jiang S
Immunopharmacol Immunotoxicol; 2024 Jun; 46(3):395-407. PubMed ID: 38627024
[TBL] [Abstract][Full Text] [Related]
37. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.
Guo J; Zhao J; Xu Q; Huang D
BMC Cancer; 2023 Oct; 23(1):967. PubMed ID: 37828435
[TBL] [Abstract][Full Text] [Related]
38. Significance of Continuous Low-Dose Lenvatinib for the Treating of the Patients with Unresectable Thyroid Carcinoma.
Murakami D; Nishimoto K; Takao S; Miyamaru S; Kadowaki T; Saito H; Takeda H; Ise M; Suyama K; Orita Y
Acta Med Okayama; 2024 Feb; 78(1):63-70. PubMed ID: 38419316
[TBL] [Abstract][Full Text] [Related]
39. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T; Barone C; Assenat E; Wermke M; Fasolo A; Merle P; Blanc JF; Grando V; Iacobellis A; Villa E; Trojan J; Straub J; Bruns R; Berghoff K; Scheele J; Raymond E; Faivre S
Br J Cancer; 2021 Jul; 125(2):190-199. PubMed ID: 33824476
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.
Personeni N; Pressiani T; Rimassa L
J Hepatocell Carcinoma; 2019; 6():31-39. PubMed ID: 30775342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
